SCHEMBL12503029

SCHEMBL12503029

CCCCOc1ccc(Cl)c(-c2nnc3c(C)nc4ccccc4n23)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ PDE2A O00408 20/20 1.00
▸ PDE10A Q9Y233 3/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12502663 0.92 PDE2A (1.00) PDE2APDE10A
SCHEMBL12502110 0.91 PDE2A (1.00) PDE2APDE10A
SCHEMBL14053987 0.91 PDE2A (1.00) PDE2APDE10A
SCHEMBL12502795 0.91 PDE2A (1.00) PDE2APDE10A
SCHEMBL12502424 0.89 PDE2A (1.00) PDE2APDE10A
SCHEMBL12502715 0.89 PDE2A (1.00) PDE2APDE10A
SCHEMBL12502200 0.89 PDE2A (1.00) PDE2APDE10A
SCHEMBL12502618 0.89 PDE2A (1.00) PDE2APDE10A
SCHEMBL12502544 0.88 PDE2A (1.00) PDE2APDE10A
SCHEMBL14054850 0.88 PDE2A (1.00) PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2670754-B1 (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES BOEHRINGER INGELHEIM INT (DE) 2017-05-24 — — EP claimed
EP-2723744-A1 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES Janssen Pharmaceutica, N.V. (BE) 2014-04-30 — — EP claimed
WO-2013000924-A1 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2013-01-03 — — WO claimed
US-11419874-B2 Treatment of tachycardia OSLO UNIVERSITY HOSPITAL HF (NO) 2022-08-23 — — US disclosed
US-20200345744-A1 TREATMENT OF TACHYCARDIA OSLO UNIVERSITY HOSPITAL HF (NO) 2020-11-05 — — US disclosed
EP-2670754-B1 (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES BOEHRINGER INGELHEIM INT (DE) 2017-05-24 — — EP disclosed
US-9540379-B2 (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-01-10 — — US disclosed
EP-2723744-A1 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES Janssen Pharmaceutica, N.V. (BE) 2014-04-30 — — EP disclosed
EP-2670754-A1 (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES Boehringer Ingelheim International GmbH (DE) 2013-12-11 — — EP disclosed
WO-2013000924-A1 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2013-01-03 — — WO disclosed
US-20120302564-A1 (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES BIOCREA GMBH (DE) 2012-11-29 — — US disclosed
WO-2012104293-A1 (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-08-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302564-A1 (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES PDE3A, PDE4A, PDE2A PDE2A 3/4885PDE10A 22/4885
US-11419874-B2 Treatment of tachycardia PDE4B, PDE2A, PDE5A PDE2A 2/4885PDE10A 65/4885
US-20200345744-A1 TREATMENT OF TACHYCARDIA PDE4B, PDE2A, PDE5A PDE2A 2/4885PDE10A 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback